TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38514823

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (n=205)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard blood pressure control (n=188)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Preexisting CSD
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Age, male sex, and increased body mass index
Number of subjects: 393
Study: 38514860

Group type: EXPERIMENTAL
Intervention: Wrist-worn digital health technology (DHT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lumbar-worn digital health technology (DHT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gait metrics from lumbar-worn DHT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gait and physical activity metrics
Number of subjects: 40
Study: 38515146

Group type: EXPERIMENTAL
Intervention: Enhanced cross-sectoral collaboration and treatment during the first 3 months following diagnosis.
Number of subjects: 270
Study: 38515149

Group type: EXPERIMENTAL
Intervention: Anlotinib-based therapy
Number of subjects: 14
Study: 38515183

Group type: EXPERIMENTAL
Intervention: Dolutegravir/lamivudine (DTG/3TC)
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Current antiretroviral regimen (CAR)
Number of subjects: 1234
Study: 38515199

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) - invasive variant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteral neuromodulation (ENM) - non-invasive approach with adhesive electrodes
Number of subjects: 0
Study: 38515201

Group type: EXPERIMENTAL
Intervention: Smart Speaker EchoDot 3rd Gen device (Amazon Echo®) for home use
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 38515275

Group type: EXPERIMENTAL
Intervention: DISC-0974 (7-56 mg, administered IV or SC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 38515445

Group type: EXPERIMENTAL
Intervention: Cognito's Evoked Gamma Therapy System (CogTx-001), self-administered daily for one hour over 6 months.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham treatment, self-administered daily for one hour over 6 months.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cognito's Evoked Gamma Therapy System (CogTx-001)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 76
Study: 38515570

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg administered by intravenous infusion on day 1 every 3 weeks (Q3W)
Number of subjects: 30
Study: 38515967

Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Number of subjects: 65
Study: 38516099

Group type: EXPERIMENTAL
Intervention: Sintilimab 200 mg on day one and oral daily anlotinib 12 mg on days 1-14 once every three weeks per cycle
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sintilimab plus anlotinib
Number of subjects: 42
Study: 38516100

Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Bromhexine
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Cyproheptadine
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Niclosamide + Bromhexine
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 995

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 995
Study: 38516258

Group type: EXPERIMENTAL
Intervention: Nature-based VR intervention (Active VR arm)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Sham VR intervention (Sham VR arm)
Number of subjects: 109
Study: 38516651

Group type: EXPERIMENTAL
Intervention: Self-sampled hrHPV testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinician-collected hrHPV tests
Number of subjects: 0
Study: 38516817

Group type: EXPERIMENTAL
Intervention: Functional connectivity (FC) in patients with NDPH
Number of subjects: 29

Group type: COMPARATOR
Intervention: Functional connectivity (FC) in healthy controls (HCs)
Number of subjects: 29
Study: 38517085

Group type: EXPERIMENTAL
Intervention: NEXUS criteria
Number of subjects: 21379

Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Number of subjects: 21379

Group type: EXPERIMENTAL
Intervention: PECARN retrospective criteria
Number of subjects: 21379

Group type: EXPERIMENTAL
Intervention: CG56 guideline
Number of subjects: 21379

Group type: EXPERIMENTAL
Intervention: PEDSPINE criteria
Number of subjects: 21379
Study: 38517235

Group type: EXPERIMENTAL
Intervention: Pralatrexate 25 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Romidepsin
Number of subjects: 0
Study: 38517242

Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 534

Group type: COMPARATOR
Intervention: HBP levels higher than 35 ng/mL
Number of subjects: 534
Study: 38517311

Group type: EXPERIMENTAL
Intervention: Smart glasses group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Anaesthesiology fellows (CA 5 years)
Number of subjects: 119
Study: 38517366

Group type: EXPERIMENTAL
Intervention: Counterforce brace (CB)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wrist orthosis (WO)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 37
Study: 38517416

Group type: EXPERIMENTAL
Intervention: Palbociclib plus an aromatase inhibitor (AI)
Number of subjects: 0
Study: 38517442

Group type: EXPERIMENTAL
Intervention: Telephone-based coaching rehabilitation intervention delivered over 9 sessions.
Number of subjects: 303

Group type: COMPARATOR
Intervention: Education-based attention control condition delivered via telephone at matched intervals.
Number of subjects: 303
Study: 38517479

Group type: EXPERIMENTAL
Intervention: Decision-Making Engagement Preferences
Number of subjects: 0
Study: 38517612

Group type: EXPERIMENTAL
Intervention: mHealth devices
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no mHealth devices)
Number of subjects: 107
Study: 38517907

Group type: EXPERIMENTAL
Intervention: albendazole-ivermectin treatment
Number of subjects: 87

Group type: COMPARATOR
Intervention: albendazole treatment
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: hookworm treatment (both arms)
Number of subjects: 87
Study: 38518104

Group type: EXPERIMENTAL
Intervention: SNP array analysis
Number of subjects: 317
Study: 38518263

Group type: EXPERIMENTAL
Intervention: Low-load, high-repetition resistance exercise (LLHR RE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Moderate-intensity continuous exercise (MIC)
Number of subjects: 24
Study: 38518434

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 3 mg/kg b.i.d. for weight < 10 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2.5 mg/kg b.i.d. for weight ≥ 10 kg and < 20 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2 mg/kg b.i.d. for weight ≥ 20 kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 2-3 mg/kg b.i.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) 1 mg/kg b.i.d.
Number of subjects: 0
Study: 38518479

Group type: EXPERIMENTAL
Intervention: Online group-based Acceptance and Commitment Therapy (ACT), 8 sessions as online group therapy.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no application made by researchers).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Online group-based ACT.
Number of subjects: 53
Study: 38518549

Group type: EXPERIMENTAL
Intervention: Domatinostat 200 mg twice daily (BD) plus avelumab 10 mg/kg every 2 weeks (2qw)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Domatinostat 200 mg BD plus avelumab 10 mg/kg 2qw
Number of subjects: 40
Study: 38518789

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 primary series (25 μg)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 booster dose (10 μg)
Number of subjects: 718

Group type: COMPARATOR
Intervention: mRNA-1273 primary series (historical comparator)
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: mRNA-1273.214 primary series and booster dose
Number of subjects: 718
Study: 38518848

Group type: EXPERIMENTAL
Intervention: Diet rich in monounsaturated fatty acids (MUFAs) (SFA: 7.1%E; MUFA: 20.7%E)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diet rich in saturated fatty acids (SFAs) (SFA: 13.4%E; MUFA: 14.4%E)
Number of subjects: 18
Study: 38519053

Group type: EXPERIMENTAL
Intervention: GD2BATs (anti-CD3×anti-GD2 bispecific antibody armed T cells)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GD2BATs
Number of subjects: 9
Study: 38519055

Group type: EXPERIMENTAL
Intervention: Odronextamab monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 0
Study: 38519416

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 40,000 IU/mL weekly infusion
Number of subjects: 101

Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 101
Study: 38519581

Group type: EXPERIMENTAL
Intervention: MAG-EPA (3g daily for 7 weeks)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo (3g daily for 7 weeks)
Number of subjects: 130
Study: 38519913

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until progression or unmanageable toxicity, combined with SBRT (45 Gy in 3 fractions)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: SBRT delivered concurrently with atezolizumab
Number of subjects: 60
Study: 38519921

Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in London
Number of subjects: 337029

Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in North-west region
Number of subjects: 337029

Group type: EXPERIMENTAL
Intervention: COVID-19 admissions in South-west region
Number of subjects: 337029

Group type: COMPARATOR
Intervention: Odds of death in regions compared to London
Number of subjects: 337029

Group type: EXPERIMENTAL
Intervention: AKI incidence
Number of subjects: 337029

Group type: COMPARATOR
Intervention: Odds of developing AKI compared to London
Number of subjects: 337029

Group type: EXPERIMENTAL
Intervention: Factors associated with higher odds of death
Number of subjects: 337029

Group type: EXPERIMENTAL
Intervention: Factors associated with higher odds of developing AKI
Number of subjects: 337029
Study: 38519937

Group type: EXPERIMENTAL
Intervention: Z-scrotoplasty
Number of subjects: 40

Group type: COMPARATOR
Intervention: Heineke-Mikulicz scrotoplasty
Number of subjects: 40
Study: 38519968

Group type: EXPERIMENTAL
Intervention: Estimated plasma volume status (ePVS) calculated using the Duarte formula.
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Preoperative ePVS derived from the Duarte formulas.
Number of subjects: 405
Study: 38519982

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) implantation
Number of subjects: 3889

Group type: COMPARATOR
Intervention: No ICD implantation (control)
Number of subjects: 3889
Study: 38519983

Group type: EXPERIMENTAL
Intervention: Health behavioural counselling based on the 5A's model, telephone follow-up (4 and 8 weeks), monitoring of physical activity
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 38519988

Group type: EXPERIMENTAL
Intervention: Tocilizumab added to standard of care (SOC) maintenance treatment, n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone, n = 25
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tocilizumab added to SOC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 50
Study: 38520001

Group type: EXPERIMENTAL
Intervention: Muscle damaging exercise in hypoxia (HYP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normoxia (CON)
Number of subjects: 0
Study: 38520030

Group type: EXPERIMENTAL
Intervention: PATH intervention (peer navigation program + mHealth web application)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual care (Ryan White Program case management services)
Number of subjects: 375
Study: 38520055

Group type: EXPERIMENTAL
Intervention: home-based, remotely supported and supervised exercise training program
Number of subjects: 24

Group type: COMPARATOR
Intervention: attention/contact wellness control
Number of subjects: 24
Study: 38520420

Group type: EXPERIMENTAL
Intervention: Glasses with green lenses
Number of subjects: 128

Group type: COMPARATOR
Intervention: Glasses with clear lenses (control)
Number of subjects: 128
Study: 38520501

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 38520670

Group type: EXPERIMENTAL
Intervention: Pepinemab (20 mg/kg) administered intravenously on Days 1 and 15 of a 28-day cycle
Number of subjects: 0
Study: 38520712

Group type: EXPERIMENTAL
Intervention: NMR-based risk score (NRS) combining lipoprotein subfractions and metabolic biomarkers relevant to NPC
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Small, dense very low density lipoprotein particles (VLDL-5)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Large, buoyant low density lipoprotein particles (LDL-1)
Number of subjects: 446
Study: 38520745

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 189

Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 189

Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 189
Study: 38521086

Group type: EXPERIMENTAL
Intervention: Pembrolizumab-chemoradiotherapy
Number of subjects: 1060

Group type: COMPARATOR
Intervention: Placebo-chemoradiotherapy
Number of subjects: 1060
Study: 38521132

Group type: EXPERIMENTAL
Intervention: Once-daily radiation therapy (66 Gy/33 fractions/6.5 weeks)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Twice-daily radiation therapy (45 Gy/30 fractions/3 weeks)
Number of subjects: 547
Study: 38521191

Group type: EXPERIMENTAL
Intervention: Iron supplementation (65.7 mg ferrous fumarate)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 38521526

Group type: EXPERIMENTAL
Intervention: Cross-sectional household survey
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Questionnaire interview, physical examination, and haemoglobin point-of-care testing
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Probability-proportional-to-size sampling and simple random sampling
Number of subjects: 4500
Study: 38521524

Group type: EXPERIMENTAL
Intervention: Tailored anticoagulant treatment based on individualised assessment of rVTE and major bleeding risks after 3 months of therapy.
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Continuation of anticoagulant treatment for patients with high rVTE and low bleeding risk.
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Discontinuation of anticoagulant treatment for patients with low rVTE risk after 3 months.
Number of subjects: 1600
Study: 38521533

Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone antagonist given once daily from day 6 of ovarian stimulation till the day of the ovulation trigger.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Dydrogesterone from the first day of ovarian stimulation till the day of ovulation trigger.
Number of subjects: 400
Study: 38521535

Group type: EXPERIMENTAL
Intervention: Return of participant-level data to parents via a coordinator
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Prereturn surveys
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Survey of physician site investigators
Number of subjects: 19
Study: 38521641

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management (GA + M)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Remote symptom monitoring (RSM)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Geriatric assessment and management plus remote symptom monitoring
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: GA + M and RSM
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Process evaluation outcomes
Number of subjects: 168
Study: 38521736

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 72
Study: 38521874

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study: 38521883

Group type: EXPERIMENTAL
Intervention: High-dose tafamidis (80/61 mg po qd)
Number of subjects: 10
Study: 38521893

Group type: EXPERIMENTAL
Intervention: 1 mg iberdomide
Number of subjects: 0
Study: 38521925

Group type: EXPERIMENTAL
Intervention: Chrononutrition Profile Questionnaire-Pregnancy (CPQ-P)
Number of subjects: 399
Study: 38521931

Group type: EXPERIMENTAL
Intervention: Produce prescription program (intervention)
Number of subjects: 0
Study: 38521946

Group type: EXPERIMENTAL
Intervention: Maximal velocity-intent resistance training (MI, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Controlled-tempo resistance training (CT, n=10)
Number of subjects: 20
Study: 38522094

Group type: EXPERIMENTAL
Intervention: Optimized RHtyper using whole-exome sequencing (WES) data
Number of subjects: 3426
Study: 38522127

Group type: EXPERIMENTAL
Intervention: Child group format
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Blended format with group sessions and automated web-based sessions
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Group-based parental involvement
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Psychoeducational brochure parental involvement
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Measurement Feedback System (MFS) on
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Measurement Feedback System (MFS) off
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Intervention overall
Number of subjects: 701
Study: 38522170

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 38522420

Group type: EXPERIMENTAL
Intervention: First-trimester anatomy ultrasound
Number of subjects: 128
Study: 38522443

Group type: EXPERIMENTAL
Intervention: Bubble continuous positive airway pressure (bCPAP)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Low-flow oxygen therapy
Number of subjects: 1240
Study: 38522503

Group type: EXPERIMENTAL
Intervention: Low serum antimüllerian hormone (AMH) concentration
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 400
Study: 38522597

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 64
Study: 38523000

Group type: EXPERIMENTAL
Intervention: High intensity statins and ezetimibe; 92% of patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9i); 28% of patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lomitapide; 26% of patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lipoprotein-apheresis; 23% of patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Null/null variants
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Defective variant
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ASCVD events
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aortic valve disease
Number of subjects: 39
Study: 38523332

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses from three consecutively manufactured lots)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (two doses)
Number of subjects: 0
Study: 38523487

Group type: EXPERIMENTAL
Intervention: Tozorakimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38523669

Group type: EXPERIMENTAL
Intervention: Food allergies (peanut, tree nuts, egg, milk)
Number of subjects: 5587

Group type: EXPERIMENTAL
Intervention: Food allergies
Number of subjects: 5587

Group type: EXPERIMENTAL
Intervention: Multiple food allergies
Number of subjects: 5587

Group type: EXPERIMENTAL
Intervention: Adults vs pediatric patients
Number of subjects: 5587
Study: 38523907

Group type: EXPERIMENTAL
Intervention: Multi-module music therapy group (rhythm-guided walking and singing training)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rhythm-guided walking group (music tempo-guided walking)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care group (no rehabilitation interventions)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multi-module music therapy group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Rhythm-guided walking group
Number of subjects: 75
Study: 38524210

Group type: EXPERIMENTAL
Intervention: Vigorous exercise (75 minutes per week for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moderate exercise (150 minutes per week for 8 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Moderate exercise
Number of subjects: 36
Study: 38524255

Group type: EXPERIMENTAL
Intervention: Biomarkers of myocardial injury or dysfunction (high sensitivity troponin and N-terminal pro B-type natriuretic peptide) measured at recruitment and follow-up
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Systemic inflammation biomarkers (C-reactive protein, IL-1β, IL-6, IL-10, and tumor necrosis factor alpha) measured at recruitment and follow-up
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance substudy performed at follow-up in 35 patients
Number of subjects: 69
Study: 38524266

Group type: EXPERIMENTAL
Intervention: Perioperative clinical hypnosis (CH)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Treatment-as-usual group (TAU)
Number of subjects: 92
Study: 38524688

Group type: EXPERIMENTAL
Intervention: Minimally invasive sacroiliac posterior fusion LinQ allograft implant
Number of subjects: 159
Study: 38524849

Group type: EXPERIMENTAL
Intervention: Erythrocyte glycocalyx sensitivity to sodium (eGCSS) in salt-sensitive females
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Erythrocyte glycocalyx sensitivity to sodium (eGCSS)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Immediate pressor response to oral salt (IPROS)
Number of subjects: 117
Study: 38524891

Group type: EXPERIMENTAL
Intervention: Affected limb after meniscectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Contralateral limb
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 30
Study: 38524902

Group type: EXPERIMENTAL
Intervention: Presence of metastases
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Young age
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tumor volume and type of local therapy modality
Number of subjects: 124
Study: 38525605

Group type: EXPERIMENTAL
Intervention: MRA treatment
Number of subjects: 840

Group type: COMPARATOR
Intervention: Non-MRA treatment
Number of subjects: 840
Study: 38525609

Group type: EXPERIMENTAL
Intervention: OCT-derived VFR
Number of subjects: 224